Top Industry News

A roundup of bio/pharmaceutical partnering news from Roche/Flare Therapeutics, Novo Nordisk/Ascendis Pharma and Royalty Pharma/Syndax.  * Roche, Flare Therapeutics In $1.8-Bn Small-Molecule Cancer Drug Pact* Novo Nordisk, Ascendis In $285-M+…

Two private equity firms, GHO Capital Partners and Ampersand Capital Partners, have agreed to acquire Avid Bioservices, a Tustin, California-based CDMO of biologics, for $1.1 billion.  Avid’s services include cGMP…

SK bioscience, a Seongnam, South Korea-based vaccines and biologics company, has completed its acquisition of a 60% stake in IDT Biologika, a Dessau-Rosslau, Germany-based CDMO of viral vaccines, cell- and…

The latest from CDMOs, CMOs, and suppliers featuring Evotec, Fujifilm Diosynth Biotechnologies and Olon.   Chemicals/Chemical API Manufacturing * Evotec To Sell Chemical API Mfg Facility To Investment Firm * Olon Provides Update…

A roundup of manufacturing news from Nektar and Accord Healthcare. Highlights below.  * Nektar to Sell PEG Mfg Facility, Reagent-Supply Business for $90 M  * Accord Healthcare Investing $65 M In…

GSK has announced an up to $800 million investment to bring drug-substance manufacturing and additional drug-product manufacturing capabilities to the company’s site in Marietta, Pennsylvania, making it the company’s largest…

AbbVie has agreed to acquire Aliada Therapeutics, a bio/pharmaceutical company focused on central nervous system diseases, for $1.4 billion.   Aliada’s lead investigational asset is ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ)…

The latest from CDMOs, CMOs, and suppliers featuring MilliporeSigma, Abzena, Rovi, Ardena, PharmaLogic, Sterling Pharma Solutions, and BSI.   Chemicals/Chemical API Manufacturing * MilliporeSigma Investing $76 M in ADC Mfg Facility Expansion *…

A roundup of news from AbbVie/ EvolveImmune, GSK and the UK government. Highlights below.  Partnering News * AbbVie, EvolveImmune in $1.4-Bn Licensing Pact for Cancer Biotherapeutics Mfg News * UK Reveals $675 M…

Sanofi reports that it is in exclusive negotiations with CD&R, an investment firm, for the potential sale of a 50% controlling stake in its consumer healthcare business, Opella.  CD&R has…